MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (MOTION)
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Sponsor: Newron Pharmaceuticals SPA
A PHASE3 clinical study on Idiopathic Parkinson's Disease, this trial is completed. The trial is conducted by Newron Pharmaceuticals SPA and has accumulated 10 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Apr 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Newron Pharmaceuticals SPA
For direct contact, visit the study record on ClinicalTrials.gov .